Uncategorized
Positive Clinical Data for PP353 Published in The Lancet’s eClinicalMedicine
Persica Pharmaceuticals’ Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet’s eClinicalMedicine First publication of clinical efficacy data for PP353, in development for chronic Low Back Pain Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain and Modic Type 1 changes PP353
Talking non-opioid pain therapies with the FT
In November 2025, our CEO Steve Ruston participated in a fireside chat with FT US Pharmaceutical Correspondent Patrick Temple-West, discussing how the pharmaceutical industry is tackling chronic pain and the growing demand for non-addictive therapies, including the potential of one-off treatments like PP353 for chronic Low Back Pain associated with Modic changes. I recently had the opportunity to speak
Q&A with Joshua Hirsch, Neurointerventionalist at Massachusetts General Hospital and Professor at Harvard Medical School
Please introduce yourself and tell us what you do I’m a neurointerventionalist at Massachusetts General Hospital and a professor at Harvard Medical School. Clinically, I’m focused full-time on spine and neurointerventional work. My journey with spine care started back in 1997, when we performed the first vertebroplasty in New England. That experience launched a deep interest in spinal interventions, especially
Persica strengthens global IP portfolio with EU patent granted for PP353
London, UK, 11 June 2025 – Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been granted a patent by the European Patent Office for PP353, its clinical stage asset. The new patent, EP3709970, was granted on 14th May 2025 and relates to injectable, thermosensitive
Persica Pharmaceuticals in the news 2025
During 2025, Persica has been featured in a number of publications across national and healthcare trade media following the announcement of positive topline data from the Phase 1b Modic Trial, a randomised, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of PP353 as a treatment for patients with cLBP associated with Modic Type 1 changes. This page collects all of
Q&A with Lloyd Czaplewski, Ph.D., CSO of Persica Pharmaceuticals
Q1) Can you tell us a bit about your background? How did you become involved in Persica? Through degree, Ph.D. and postdoc I was a microbial geneticist. I was always more interested in the translation of research and so moved into the biotech industry. I was lucky to work with some amazing people across a wide range of technical skills
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain The PP353 clinical trial met the primary endpoint and demonstrated statistically significant, clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain with Modic Type 1 changes Meaningful reductions in pain
Q&A with Steve Ruston, Chief Executive Officer
Q&A with Steve Ruston, Chief Executive Officer What is Persica’s mission? Our mission is to help people suffering with chronic Low Back Pain (cLBP) – a debilitating condition that significantly affects the quality of life of millions of people, many of whom are not helped by existing treatments. We are developing a radical new treatment for a subgroup of patients
Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025
Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025 Persica is developing PP353, a potentially curative, opioid-sparing treatment for patients with chronic Low Back Pain Persica’s work builds on substantial evidence that chronic Low Back Pain with Modic changes can be caused by a bacterial infection of the vertebral disc PP353 is
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held, clinical stage pharmaceutical company developing an antibiotic formulation for intradiscal injection to treat chronic Low Back Pain (cLBP) and disability associated with bone oedema (Modic 1), which is caused by bacterial